VBL Therapeutics announced the nomination of industry veterans Ron Cohen, M.D., and Philip Serlin, C.P.A. to stand for election to the Board of Directors at VBL's extraordinary general meeting of shareholders, scheduled for February 11, 2015. Both individuals currently are leaders of biotechnology companies publicly traded in the US: Dr. Cohen serves as the President and Chief Executive Officer of Acorda Therapeutics Inc. and Mr. Serlin is Chief Financial and Operating Officer of BioLineRx Ltd. In addition to his position at Acorda, Dr. Cohen is a member of the Executive Committee and Vice Chair of the Health Section of the Biotechnology Industry Organization (BIO), and serves on the Board of Directors of Dyax Corp. He previously served as the Director and Chairman of the New York Biotechnology Association, and also serves as a member of the Columbia-Presbyterian Health Sciences Advisory Council.